Talk:Bavituximab
| This is the talk page for discussing improvements to the Bavituximab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Bavituximab.
|
 | The following Wikipedia contributor has declared a personal or professional connection to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
|
 | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
 | The contents of the Bavituximab page were merged into Peregrine Pharmaceuticals. For the contribution history and old versions of the merged article please see its history. |
- Redirect now converted back to independent article.
Which type of analog
Could someone possibly disambiguate the use of analog in the intro. Rod57 (talk) 01:26, 11 August 2009 (UTC)
Any more info on "3G4, 2aG4, 9d2 and Hu3g4"?
Does any one know who developed these analogs? Is it the same company that developed Bavituximab (Peregrine Pharma)?Johnfravolda (talk) 05:56, 11 August 2009 (UTC)
Sources
I used the references box at the top of this page to search pubmed for reviews. There were only two:
- PMID 21843081 is too close to failing WP:INDY as its disclosure says: "DE Gerber receives research support from Peregrine Pharmaceuticals. PE Thorpe serves as a paid consultant, holds stock and has a sponsored research agreement with Peregrine Pharmaceuticals." And the middle author is the inventor, which for some reason they don't disclose. This is not the kind of source I will use for an article about a drug in development
- PMID 21867942 is independent. and I used it.
Outside of those there are few independent sources. I used Adis, which is independent, and I used Peregrines 10-K and a press release to describe the origin of the antibody; the 10-K especially is a highly regulated document so is OK. Jytdog (talk) 06:06, 12 February 2016 (UTC)
Later analysis of SUNRISE patients who went on to have immunotherapy
They seem to have benefited according to [1] - but that was probably based on a press release so could wait for a MEDRS. - Rod57 (talk) 23:20, 3 December 2017 (UTC)